Evidence map›Paper›PMID 40716144›Full record

ArticleVaccine2025

Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.

Joann Diray-Arce, Ana C Chang, Sara Moradipoor, Donato Amodio, Bruce Carleton, Wan-Chun Chang, Nigel W Crawford, Meagan Karoly, Annmarie Hoch, Kerry McEnaney and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Joann Diray-ArcePrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: joann.arce@childrens.harvard.edu.
Ana C ChangPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Sara MoradipoorDepartment of Pediatrics, University of Alberta, Edmonton, AB T6G 1C9, Canada.
Donato AmodioClinical and Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
Bruce CarletonDepartment of Pediatrics and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.
Wan-Chun ChangDepartment of Pediatrics and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.
Nigel W CrawfordMurdoch Children's Research Institute (MCRI_AEFI-CAN) & University of Melbourne, Parkville, VIC 3052, Australia.
Meagan KarolyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Annmarie HochPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Kerry McEnaneyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Tahir S KafilDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Mahitha DonthireddyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Sarah K SteltzPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
Simon D van HarenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Asimenia AngelidouPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Kinga K SmolenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Hanno SteenHarvard Medical School, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Jessica Lasky-SuHarvard Medical School, Boston, MA 02115, USA; Channing Division of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Huyen TranMonash University, Melbourne, VIC 3004, Australia.
Peter LiuUniversity of Ottawa Heart Institute, Ottawa, ON K1W 4W7, Canada.
C Buddy CreechVaccine Research Program, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Clare L CutlandAfrican Leadership in Vaccinology Expertise (Wits-Alive), Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg 2050, South Africa.
Helen Petousis-HarrisGlobal Vaccine Data Network and School of Population Health, University of Auckland, 1142, New Zealand.
Ishac NazyDepartment of Medicine McMaster University, Hamilton, ON L8S 4K1, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Rae S M YeungCell and Systems Biology Research Program, The Hospital for Sick Children, Departments of Paediatrics, Immunology and Institute of Medical Sciences, University of Toronto, Toronto, ON M5G 1X8, Canada.
Sonali KochharGlobal Healthcare Consulting, New Delhi 110024, India; University of Washington, Seattle, WA 98915, USA.
Steve BlackGlobal Vaccine Data Network and School of Population Health, University of Auckland, 1142, New Zealand.
Nicholas WoodUniversity of Sydney, Sydney, NSW 2006, Australia.
Dale NordenbergThriive, Bronx, NY, USA; Safety Platform for Emergency vACcines (SPEAC), Brighton Collaboration, The Task Force for Global Health, Decatur, GA 30030, USA.
Paolo PalmaClinical and Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
Inna G OvsyannikovaVaccine Research Group, Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Richard B KennedyVaccine Research Group, Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Gregory A PolandVaccine Research Group, Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Al OzonoffPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Robert T ChenBrighton Collaboration, Task Force for Global Health, Decatur, GA 30030, USA.
Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Karina A TopDepartment of Pediatrics, University of Alberta, Edmonton, AB T6G 1C9, Canada; Li Ka Shing Institute of Virology and Women's and Children's Health Research Institute, University of Alberta, Edmonton, AB T6G 2E1, Canada; Departments of Community Health & Epidemiology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
International Network of Special Immunization Services (INSIS) Members

Funding

Immunometabolic signatures of BCG-induced neonatal trained immunityK08AI168487 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Asimenia Angelidou · 2023 to 2026
$704k
NCIRD CDC HHS H23 IP000942NIAID NIH HHS K08 AI168487
6 · The paper itself

Abstract

The International Network of Special Immunization Services (INSIS) was established to investigate the causes and risk factors of rare adverse events following immunizations (AEFIs) and develop immunization strategies for mitigating or preventing risk for individuals with prior AEFIs or at risk of AEFIs. INSIS integrates clinical data with multi-omic technologies (e.g., transcriptomics, proteomics, metabolomics) through a global consortium of clinical networks, leading immunology, pharmacogenomics teams to uncover the molecular mechanisms behind AEFIs. The network ensures accurate and standardized data collection and analysis through rigorous data management and quality assurance processes. INSIS also implements harmonized case definitions and protocols for collecting data and samples related to rare AEFIs, such as myocarditis, pericarditis, and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) after COVID-19 vaccinations. This protocol outlines the comprehensive approach to enhance risk-benefit assessments of vaccines across populations, identify actionable biomarkers to inform discovery and development of safe vaccines, and support personalized vaccination strategies.

Indexed as

BiomarkersCOVID-19 VaccinesSystems BiologyVaccinationVaccinesCOVID-19HumansLongitudinal StudiesRisk AssessmentSARS-CoV-2BiomarkersCOVID-19 VaccinesVaccinesAdverse event of following immunizationAdversomicsAEFIBiomarker discoveryCOVID-19 vaccinesINSISMulti-omicsMyocarditisPericarditisPF4Systems biologyTTSVaccine safetyVITT

Identifiers

PMID40716144
PMCPMC13388017

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.